MA51753A - Éléments de régulation de la transcription et utilisations associées - Google Patents
Éléments de régulation de la transcription et utilisations associéesInfo
- Publication number
- MA51753A MA51753A MA051753A MA51753A MA51753A MA 51753 A MA51753 A MA 51753A MA 051753 A MA051753 A MA 051753A MA 51753 A MA51753 A MA 51753A MA 51753 A MA51753 A MA 51753A
- Authority
- MA
- Morocco
- Prior art keywords
- elements
- transcription regulation
- associated uses
- transcription
- regulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862626561P | 2018-02-05 | 2018-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51753A true MA51753A (fr) | 2020-12-16 |
Family
ID=67478520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051753A MA51753A (fr) | 2018-02-05 | 2019-02-05 | Éléments de régulation de la transcription et utilisations associées |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210162073A1 (fr) |
EP (1) | EP3749756A4 (fr) |
JP (2) | JP7381494B2 (fr) |
CN (1) | CN111936621A (fr) |
MA (1) | MA51753A (fr) |
WO (1) | WO2019153009A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018281280A1 (en) | 2017-06-07 | 2020-01-16 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
CA3086942A1 (fr) * | 2018-02-07 | 2019-08-15 | Genethon | Elements regulateurs hybrides |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
KR20220098384A (ko) * | 2019-11-19 | 2022-07-12 | 아스클레피오스 바이오파마슈티컬, 인크. | 폼페병 및 리소좀 장애를 치료하기 위한 간-특이적 프로모터를 포함하는 치료적 아데노-관련 바이러스 |
EP4107259A1 (fr) * | 2020-02-18 | 2022-12-28 | Vrije Universiteit Brussel | Nouvelle combinaison d'éléments régulateurs d'acide nucléique et procédés et utilisations associés |
AR126660A1 (es) * | 2021-07-28 | 2023-11-01 | Univ Brussel Vrije | Mejorando la eficacia de la terapia génica dirigida a músculos |
WO2023173078A2 (fr) * | 2022-03-11 | 2023-09-14 | Homology Medicines, Inc. | Doubles vecteurs bidirectionnels d'expression de promoteur et leurs utilisations |
WO2024006775A2 (fr) * | 2022-06-27 | 2024-01-04 | Astellas Gene Therapies, Inc. | Compositions et méthodes pour le traitement de dystrophies myotoniques |
CN118715025A (zh) * | 2022-10-08 | 2024-09-27 | 凌意(杭州)生物科技有限公司 | 用于增强基因表达的构建体 |
CN118064436B (zh) * | 2024-04-18 | 2024-07-26 | 上海凌医生物科技有限公司 | 一种增强基因表达的嵌合启动子 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004535801A (ja) * | 2001-05-24 | 2004-12-02 | ジェンザイム コーポレイション | 筋特異的発現ベクター |
US8021875B2 (en) * | 2001-08-27 | 2011-09-20 | Roche Madison Inc. | Methods for expression of transgenes |
US20070161031A1 (en) * | 2005-12-16 | 2007-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Functional arrays for high throughput characterization of gene expression regulatory elements |
KR20150020250A (ko) | 2012-06-19 | 2015-02-25 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 당뇨병을 치료하기 위한 조성물 및 방법 |
SG11201605906UA (en) | 2014-01-21 | 2016-08-30 | Univ Bruxelles | Muscle-specific nucleic acid regulatory elements and methods and use thereof |
US10781459B2 (en) * | 2014-06-20 | 2020-09-22 | University Of Florida Research Foundation, Incorporated | Methods of packaging multiple adeno-associated virus vectors |
US11020443B2 (en) | 2015-04-23 | 2021-06-01 | University Of Massachusetts | Modulation of AAV vector transgene expression |
-
2019
- 2019-02-05 MA MA051753A patent/MA51753A/fr unknown
- 2019-02-05 US US16/966,521 patent/US20210162073A1/en active Pending
- 2019-02-05 JP JP2020564045A patent/JP7381494B2/ja active Active
- 2019-02-05 CN CN201980015960.6A patent/CN111936621A/zh active Pending
- 2019-02-05 EP EP19748361.3A patent/EP3749756A4/fr active Pending
- 2019-02-05 WO PCT/US2019/016692 patent/WO2019153009A1/fr unknown
-
2023
- 2023-11-02 JP JP2023188066A patent/JP2024012479A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2021512649A (ja) | 2021-05-20 |
EP3749756A1 (fr) | 2020-12-16 |
JP7381494B2 (ja) | 2023-11-15 |
CN111936621A (zh) | 2020-11-13 |
EP3749756A4 (fr) | 2021-12-08 |
US20210162073A1 (en) | 2021-06-03 |
WO2019153009A1 (fr) | 2019-08-08 |
JP2024012479A (ja) | 2024-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51753A (fr) | Éléments de régulation de la transcription et utilisations associées | |
MA50502A (fr) | Adénovirus et utilisations associées | |
MA51288A (fr) | Analogues d'incrétine et leurs utilisations | |
MA50618A (fr) | Polyrhérapies et leurs utilisations | |
MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
MA44262A (fr) | Bioconjugués et utilisations de ceux-ci | |
MA55083A (fr) | Polyribonucléotides et leurs utilisations cosmétiques | |
MA46672A (fr) | Immunoglobulines et utilisations de celles-ci | |
ITUA20161846A1 (it) | Procedimento ed architettura di regolazione remota di un'audioprotesi | |
ES2981470T3 (es) | Composiciones y método de pulpa kraft reticulada | |
DK3532064T3 (da) | Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser | |
MA43270A (fr) | Inhibiteur de la c1 estérase humaine recombinante et ses utilisations | |
GB2589747B (en) | Photodetector and method of manufacture thereof | |
MA49905A (fr) | Polyesteramines et polyesterquats | |
DK3231405T3 (da) | Fremgangsmåde til at forudsige udskillelser og indretning hertil | |
MA44968A (fr) | Esters d'oxaborole et leurs utilisations | |
IT201700050577A1 (it) | Supporto nanofunzionalizzato e metodo di realizzazione | |
FR3040246B1 (fr) | Laser terahertz, source terahertz et utilisation d'un tel laser terahertz | |
DK3655521T3 (da) | Variant af olieholdig gær og dens anvendelse til fremstilling af lipider | |
DK3345501T3 (da) | Paraply og metode til fremstilling af paraplyen | |
MA52202A (fr) | Compositions d'érénumab et utilisations de celles-ci | |
FR3080376B1 (fr) | Autoanticorps hautement sialyles et leurs utilisations | |
DK3640243T3 (da) | Piperazinderivater til behandling af hypertension og/eller fibrose | |
DK3423062T3 (da) | Sultiam til behandlingen af søvnapnø |